Physician profile
Sarah E Huffstetler
NPI 1629517834
$3,264.19
in general payments reported to CMS, 2019-2025
19 companies · $696 in 2025
The $696 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $753 · 2022: $380 · 2023: $666 · 2024: $770 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,356.85 | 2021-2025 | |
| Pfizer INC. | $350.35 | 2021-2025 | |
| Novo Nordisk INC | $338.34 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $299.57 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $222.43 | 2021-2024 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $214.28 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $120.54 | 2021-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $80.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $56.73 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $39.15 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $36.50 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $26.80 | 2022 | |
| Amgen INC. | $25.35 | 2022 | |
| Mirum Pharmaceuticals, INC. | $24.22 | 2025 | Cholbam |
| Merck Sharp & Dohme LLC | $20.10 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.05 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2021 | |
| Genentech USA, INC. | $1.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Huffstetler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.